Study Title
PROstate-specific Membrane Antigen DosImetry- Guided endoradiotherapY: A Randomized- Controlled, Single-blind, Pilot Study of Personalized vs. Fixed-activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Study Details
Description:
Researchers will compare participants receiving a personalized regime to participants receiving the standard fixed-activity regime of 177Lu-PSMA-617 to see if the activity can be safely increased through personalization based on renal dosimetry (i.e. the measure of how much radiation is actually delivered to the kidney).
Sponsor:
Jean-Mathieu Beauregard
Contacts:
Marie-Christine Dubé, Ph.D.marie-christine.dube@crchudequebec.ulaval.ca
418-525-4444
Government Study Link:
NCT06943495 - Click here to see study onClinicalTrials.gov
Drug Details
177Lu-PSMA-617
Isotope(s):
- LUTETIUM-177
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: DOTA
